Osteoporosis after organ transplantation

American Journal of Medicine

Volumn 104, Issue 5, 1998, Pages 459-469

  Rodino, Maria A ^a   Shane, Elizabeth ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCIUM; CALMODULIN; CYCLOSPORIN; GLUCOCORTICOID; PARATHYROID HORMONE; TACROLIMUS; TESTOSTERONE; VITAMIN D;

BILIARY CIRRHOSIS; BONE ATROPHY; BONE MASS; CALCIUM BLOOD LEVEL; DENSITOMETRY; DOSE RESPONSE; ENZYME INHIBITION; HEART TRANSPLANTATION; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG DISEASE; LUNG TRANSPLANTATION; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; TESTOSTERONE BLOOD LEVEL; THYROID FUNCTION TEST; VITAMIN BLOOD LEVEL;

BONE AND BONES; BONE DENSITY; FEMALE; FRACTURES, BONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; OSTEOPOROSIS; RISK FACTORS; TRANSPLANTATION IMMUNOLOGY;

EID: 0032076696     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00081-3     Document Type: Review

References (91)

1. 1. United Network of Organ Sharing (UNOS) OPTN/SR 1996 annual report-graft/patient survival.
2. 2. Hosenpud JD, Novick RJ, Bennett LE, The registry of the International Society for Heart and Lung Transplantation: Thirteenth Official Report-1996. J Heart Lung Transplant. 1996;15:655-674.
3. 3. Kahan BD. Cyclosporine. NEJM. 1989;321:1725-1738.
4. 4. Epstein S, Shane E. Transplantation osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. New York: Academic Press; 1996:947-957.
5. 5. Shane E, Epstein S. Immunosuppressive therapy and the skeleton. Trends Endocrinol Metab. 1994;4:169-175.
6. 6. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents on the skeleton. J Bone Miner Res. 1996; 11:1-7.
7. 7. Lukert BP. Glucocorticoid-induced osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. New York: Academic Press; 1996:801-820.
8. 8. Lukert B, Kream BE. Clinical and basic aspects of glucocorticoid action in bone. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of Bone Biology. New York: Academic Press; 1996:533-548.
9. 9. Reid IR, Ibbertson HK. Evidence of decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics. Horm Res. 1987; 27:200-204.
10. 10. Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res. 1989;4:137-141.
11. 11. Paz-Pacheco E, El-Hajj Fuleihan G, LeBoff MS. Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J Bone Miner Res. 1995;10:1713-1718.
12. 12. Movsowitz C, Epstein S, Fallon M, et al. Cyclosporin A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology. 1988;123:2571-2577.
13. 13. Movsowitz C, Epstein S, Ismail F, et al. Cyclosporin A in the oophorectomized rat: unexpected severe bone resorption. J Bone Miner Res. 1989;4:393-398.
14. 14. Schlosberg M, Movsowitz C, Epstein S, et al. The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology. 1989;124:2179-2184.
15. 15. Stein B, Halloran BP, Reinhardt T, et al. Cyclosporin A increases synthesis of 1,25 dihydroxyvitamin D3 in the rat and mouse. Endocrinology. 1991;128:1369-1373.
16. 16. Bowman AR, Dass DA, Dissanayake IR, et al. The role of testosterone in cyclosporine-induced osteopenia. J Bone Miner Res. 1997;12: 607-615.
17. 17. Joffe I, Katz I, Jacobs T, et al. 17 Beta-estradiol prevents osteopenia in the oophorectomized rat treated with cyclosporin A. Endocrinology. 1992;130:578-586.
18. 18. Stein B, Takizawa M, Katz I, et al. Salmon calcitonin prevents cyclosporin A induced high turnover bone loss. Endocrinology. 1991; 129:92-98.
19. 19. Sass DA, Bowman AR, Marshall I, et al. The bisphosphonate, alendronate, reverses cyclosporine induced osteopenia in the aged rat. J Bone Miner Res. 1995;10:S256. Abstract.
20. 20. Aubia J, Masramon J, Serrano, et al. Bone histology in renal transplant patients receiving cyclosporin. Lancet. 1988;i:1048-1049.
21. 21. Wilmink JM, Bras J, Surachno S, et al. Bone repair in cyclosporin treated renal transplant patients. Transplant Proc. 1989;21:1492-1494.
22. 22. Thiebaud D, Krieg MA, Gillard-Berguer D, et al. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest. 1996;26:549-555.
23. 23. Hawkins FG, Leon M, Lopez MB, et al. Bone loss and turnover in patients with liver transplantation. Hepato-Gastroenterol. 1994;41: 158-161.
24. 24. Cvetkovic M, Mann G, Romero D, et al. Deleterious effects of long term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation. 1994;57:1231-1237.
25. 25. Morris R. New immunosuppressive drugs for transplantation. In: Emery R, Miller L, eds. Handbook of Cardiac Transplantation. Philadelphia: Hanley and Belfus; 1996:109.
26. 26. Stempfle HU, Wehr U, Meiger B, et al. Effect of FK506 (Tacrolimus) on trabecular bone loss shortly after cardiac transplantation. J Bone Miner Res. 1996;11:S127. Abstract.
27. 27. Apostlinas S, Sheiner P, Genyk Y, et al. Prospective comparison of bone loss with tacrolimus and cyclosporin A after organ transplantation. J Bone Miner Res. 1997;12S. Abstract.
28. 28. Bryer H, Isserow JA, Armstrong EC, et al. Azathioprine alone is bone sparing and does not alter cyclosporin A induced bone loss in the rat. J Bone Miner Res. 1995;10:1191-1200.
29. 29. Joffe I, Katz I, Sehgal S, et al. Lack of change of cancellous bone volume with short term use of the new immunosuppressant rapamycin in rats. Calcif Tissue Int. 1993;53:45-52.
30. 30. Dissanayake I, Goodman C, Bowman A, et al. Mycophenolate mofetil: a promising new immunosuppressant which does not cause bone loss in the rat. 1997. Transplantation. 1998. In press.
31. 31. Goodman WG, Coburn JW, Slatopolsky E, Salusky I. Renal osteodystrophy in adults and children. In: Favus MI, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 3rd ed. Philadelphia: Lippincott-Raven; 1996;341-360.
32. 32. Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral bone density after renal transplantation. NEJM. 1991;325:544-550.
33. 33. Horber FF, Casez JP, Steiger U, et al. Changes in bone mass early after kidney transplantation. J Bone Miner Res. 1994;9:1-9.
34. 34. Kwan JTC, Almond MK, Evans K, Cunningham J. Changes in total body bone mineral content and regional bone mineral density in renal patients following renal transplantation. Miner Electrolyte Metab. 1992;18:166-168.
35. 35. Pichette V, Bonnardeaux A, Prudhomme L, et al. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kid Dis. 1996;28:105-114.
36. 36. Grotz WH, Mundinger A, Gugel B, et al. Bone fracture and osteodensitometry with dual energy x-ray absorptiometry in kidney transplant recipients. Transplantation. 1994;58:912-915.
37. 37. Nisbeth U, Lindh E, Ljunghall S, et al. Fracture frequency after kidney transplantation. Transplant Proc. 1994;26:1764.
38. 38. Torres A, Machado M, Concepcion MT, et al. Influence of vitamin D receptor genotype on bone mass after renal transplantation. Kidney Int. 1996;50:1726-1733.
39. 39. Muchmore JS, Cooper DKC, Ye Y, et al. Loss of vertebral bone density in heart transplant patients. Transplant Proc. 1991;23: 1184-1185.
40. 40. Lee AH, Mull RL, Keenan GF, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med. 1994;96:35-41.
41. 41. Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197-207.
42. 42. Kanis JA, Melton LJ, Christiansen C, et al. Perspective. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-1141.
43. 43. Shane E, Rivas M, Silverberg SJ, et al. Osteoporosis after cardiac transplantation. Am J Med. 1993;94:257-264.
44. 44. Rich GM, Mudge GH, Laffel GL, LeBoff MS. Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant. 1992; 11:950-958.
45. 45. Shane E, Rivas M, Staron RB, et al. Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab. 1996;81:1740-1746.
46. 46. Leidig-Bruckner G, Edberwein S, Czeczatka D, et al. Incidence of osteoporosis fractures after liver and heart transplantation. J Bone Min Res. 1997;12(suppl 1):S145.
47. 47. Sambrook PN, Kelly PJ, Keogh A, et al. Bone loss after cardiac transplantation: a prospective study. J Heart Lung Transplant. 1994; 13:116-121.
48. 48. Van Cleemput J, Daenen W, Nijs J, et al. Timing and quantification of bone loss in cardiac transplant recipients. Transplant Int. 1995; 8:196-200.
49. 49. Berguer DG, Krieg M-A, Thiebaud D, et al. Osteoporosis in heart transplant recipients: A longitudinal study. Transplant Proc. 1994; 26:2649-2651.
50. 50. Henderson NK, Sambrook PN, Kelly PJ, et al. Bone mineral loss and recovery after cardiac transplantation. Lancet. 1995;ii:905.
51. 51. Shane E, Rivas M, McMahon DJ, et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab. 1997;82:1497-1506.
52. 52. Sambrook PN, Kelly PJ, Fontana D, et al. Mechanics of rapid bone loss following cardiac transplantation. Osteoporosis Int. 1994;4: 273-276.
53. 53. Prummel MF, Wiersinga WM, Lips P, et al. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab. 1991;72:382-386.
54. 54. Lems WF, Gerrits MI, Jacobs JWG, et al. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 1996;55: 288-293.
55. 55. Aris RM, Neuringer IP, Weiner MA, et al. Severe osteoporosis before and after lung transplantation. Chest. 1996;109:1176-1183.
56. 56. Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med. 1996;101:262-269.
57. 57. Bachrach LK, Loutit CW, Moss RB, Marcus R. Osteoporosis in adults with cystic fibrosis. Am J Med. 1994;96:27-34.
58. 58. Donovan DS Jr, Papadopoulos A, Staron RB, et al. Osteoporosis is associated with vitamin D deficiency in adults with severe cystic fibrosis. J Bone Miner Res. 1996;11:541. Abstract.
59. 59. Schulman L, Addesso V, Staron RB, Shane E. Sacral insufficiency fracture after lung transplantation. J Heart Lung Transplant. 1997; 16:1081-1085.
60. 60. Hodgson SF, Dickson ER, Wahner HW, et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med. 1980;103;855-860.
61. 61. Bikle DD, Genant MD, Conn C, et al. Bone disease in alcohol abuse. Ann Intern Med. 1985;103:42-48.
62. 62. Friday KE, Howard GA. Ethanol inhibits human bone cell proliferation and function in vitro. Metabolism. 1991;40:562-565.
63. 63. Diamond T, Stiel D. Osteoporosis in hemochromatosis. Iron excess, gonadal deficiency or other factors? Ann Intern Med. 1989; 110: 430-436.
64. 64. Stellon AJ, Davies A, Compston J. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology. 1985;89:1078-1083.
65. 65. Haagsma EB, Thijn CJP, Post JG. Bone disease after liver transplantation. J Hepatol. 1988;6:94-100.
66. 66. Arnold JC, Hauser R, Ziegler R, et al. Bone disease after liver transplantation. Transplant Proc. 1992;24:2709-2710.
67. 67. McDonald JA, Dunstan CR, Dilworth P, et al. Bone loss after liver transplantation. Hepatology. 1991;14:613-619.
68. 68. Navasa M, Monegal A, Guanabens N, et al. Bone fractures in liver transplant patients. Br J Rheumatol. 1994;33:52-55.
69. 69. Eastell R, Dickson ER, Hodgson SF, et al. Rates of bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology. 1991;14:296-300.
70. 70. Meys E, Fontanges E, Fourcade N, et al. Bone loss after orthotopic liver transplantation. Am J Med. 1994;97:445-450.
71. 71. Peris P, Navasa M, Guanabens N, et al. Sacral stress fracture after liver transplantation. Br J Rheumatol. 1993;32:702-704.
72. 72. Kelly P, Atkinson K, Ward RL, et al. Reduced bone mineral density in men and women with allogeneic bone marrow transplantation. Transplantation. 1990;50:881-883.
73. 73. Carlson K, Simonsson B, Ljunghall S. Acute effects of high dose chemotherapy followed by bone marrow transplantation on serum markers of bone metabolism. Calcif Tiss Int. 1994;55:408-411.
74. 74. Schubert MA, Sullivan KM, Schubert MM, et al. Gynecologic abnormalities following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1990;5:425-430.
75. 75. Stern IM, Chesnut CH III, Bruemmer B, et al. Bone density loss during treatment of chronic GVHD. Bone Marrow Transplant. 1996; 17:395-400.
76. 76. Seeman E. Osteoporosis: trials and tribulations. Am J Med. 1997; 103(suppl 2A):74-89.
77. 77. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991;114:919-923.
78. 78. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheum. 1994;33:348-350.
79. 79. Diamond T, McGiugan L, Barbagalla S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med. 1995;98:459-463.
80. 80. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. NEJM. 1997; 337:382-387.
81. 81. Shane E, Thys-Jacobs S, Papadopoulos A, et al. Antiresorptive therapy prevents bone loss after cardiac transplantation (CTX). J Bone Miner Res. 1996;11:635. Abstract.
82. 82. Fan S, Almond MK, Ball E, et al. Randomized prospective study demonstrating prevention of bone loss by pamidronate during the first year after renal transplantation. J Am Soc Nephrol. 1996;7: A2714. Abstract.
83. 83. Riemens SC, Oostdijk A, van Doormaal J, et al. Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alpha calcidiol. Osteoporosis Int. 1996;6:213-218.
84. 84. Saag K, Emkey R, Gruber B, et al. Alendronate for the management of glucocorticoid-induced osteoporosis: results of a multi-center U.S. study. Arthritis Rheum. 1997;40(suppl):S136.
85. 85. Montemurro L, Schiraldi G, Fraioli P, et al. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tis Int. 1991;49:71-76.
86. 86. Nishieka T, Kurayama M, Yasuda T, et al. Nasal administration of salmon calcitonin for prevention of glucocorticoid-induced osteoporosis in children with nephrosis. J Pediatrics. 1991;118:703-707.
87. 87. Valero MA, Loinaz C, Larrodera L, et al. Calcitonin and bisphosphonate treatment and bone loss after liver transplantation. Calcif Tiss Int. 1995;57:15-19.
88. 88. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis - a comparison of calcium, calcitriol and calcitonin. NEJM. 1993;328:1747-1752.
89. 89. Van Cleemput J, Daenen W, Geusens P, et al. Prevention of bone loss in cardiac transplant recipients. A comparison of bisphosphonates and vitamin D. Transplantation. 1996;61:1495-1499.
90. 90. Meunier PJ, Brancon D, Chavassieux P, et al. Treatment with fluoride. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis. Copenhagen: Osteopress; 1987;824-828.
91. 91. Meys E, Terreaux-Ouvert F, Beaume-Six T, et al. Effects of calcium, calderol and monofluorophosphate on lumbar bone mass and parathyroid function in patients after cardiac transplantation. Osteoporosis Int. 1993;3:329-332.